A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Trial Details

NCT ID

NCT07680764

Phase

PHASE2

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Pumitamig
• Imzokitug
• Pemetrexed
• Cisplatin
• Carboplatin
• Paclitaxel

Locations (sample)

• Washington D.C., District of Columbia, United States|38.89511,-77.03637
• Athens, Georgia, United States|33.96095,-83.37794
• Lexington, Kentucky, United States|37.98869,-84.47772
• Baltimore, Maryland, United States|39.29038,-76.61219
• Hattiesburg, Mississippi, United States|31.32712,-89.29034

Key Eligibility Criteria

• Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent un…
• Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
• Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the…
• Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.